Data concerning the persistence of psoriatic arthritis (PsA) patients on biologics in real clinical practice are insufficient. Objectives: to analyze the survival of biological treatment of PsA and detect possible predictors of persistence on biologics. Methods PsA patients from Moscow Unified Arthritis ...
January 31, 2012 — Psoriatic arthritis can be helped with early, aggressive treatment, including biologics, and if surgery is required for pain relief or to restore function, special care should be taken to prevent postoperative infections, according to a review published in the January 2012 ...
Juvenile idiopathic arthritis (JIA) is the most common rheumatic immune disease observed in children under the age of 16 years with an annual prevalence of 70.2/100,0001. Since TNF-α has been shown to play a key role in its pathogenesis2, treatment strategies to neutralize TNF-α have been...
Check access to the full text by signing in through your organization. Access throughyour organization References (0) Cited by (0) Commercial Support: NA. View full text Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study...
"Chronic inflammatory diseases already confer a significant economic burden for patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis," Cécile Gaujoux-Viala, MD, from Nîmes University Hospital in France, told reporters attending a news conference. In fact, one-fifth of...
tnf inhibitors. also known as a tnf blocker, this type of biologic blocks a protein called tnf, which drives inflammation in diseases like ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. there are several tnf inhibitors, and they all work a little differently, so if one ...
YESINTEK is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, increasing patient access to more cost-effective treatment options for use in the treatment of common chronic autoimmune diseases. YESINTEK will be available in all the sam...
Canavan T, Elmets C, Cantrell W, Evans J, Elewski B. Anti-IL-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2015;17(1):33–47. ArticleGoogle Scholar
AEoSI include, but are not limited to, infections, malignancies, and joint complaints or new-onset psoriatic arthritis. All adverse events reported spontaneously by the participant or observed by the investigator will be recorded in the CRF during the study period (18 months). Drug trough ...
Studies of psoriatic arthritis were not included. Data were independently abstracted by 2 investigators and reviewed by 6 investigators. The selection criteria were met by 22 randomized controlled trials enrolling a total of 10,183 patients. MACE during the placebo-controlled phase of treatment in ...